Qure AI vs Viz.ai (2026)
The same underlying technology, detection on an image, pointed at opposite failures in opposite health systems. Viz.ai detects and then mobilises: its stroke product received the first ever authorization for computer aided triage and notification, and the platform's real work is getting the treating team moving, with outcome evidence measuring care delivery rather than model accuracy. Qure detects where there may be no team to mobilise, holding the broadest chest radiograph regulatory footprint in the market across nine products and deploying into screening programmes and settings where radiologist capacity is thinnest. For a United States health system with an interventional pathway, Viz.ai is the product that shortens time to treatment. For a programme reading large volumes of chest imaging with limited specialist availability, Qure is doing the read itself, and that raises the harder question of what happens to the patients the model misses when nobody else is looking at the film.
- The regulatory breadth across chest radiography is the widest in the market, spanning nine products across radiography and computed tomography, with published device dossiers behind them.
- It is designed for settings where specialist reading capacity is scarce, including public health screening, which is a different deployment problem from reprioritising a hospital worklist.
- On premise installation is supported and stated, which removes the data transfer question rather than managing it, and suits deployments where cross border transfer is not acceptable.
- The authorization history is the deepest in imaging AI, beginning with the first ever clearance for computer aided triage and notification, across more than fifty cleared algorithms spanning imaging, cardiac tracing and echocardiography.
- The evidence measures care delivery rather than detection, which is the harder result to produce and the one that corresponds to patient benefit.
- The communication layer is the product: the finding reaches the treating team automatically, which is what converts a detection into a faster intervention.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Qure AI and Viz.ai are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Qure AI its top capability grade on several axes, including AI Centrality, Model and Technology Transparency and Clinical and Operational Evidence. Set against Viz.ai, Qure AI grades higher on several axes, including Model and Technology Transparency, Model Supply Chain Disclosure and Security Certifications and Trust Center. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Viz.ai its top capability grade on several axes, including AI Centrality, Autonomy and Oversight Model and Clinical and Operational Evidence. Set against Qure AI, Viz.ai grades higher on Autonomy and Oversight Model and EHR and Interoperability Depth. Its thinnest published disclosure sits on Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Qure AI or Viz.ai?
On the axes where the AI Health Index separates them, Qure AI grades higher on several axes, including Model and Technology Transparency, Model Supply Chain Disclosure and Security Certifications and Trust Center, and Viz.ai grades higher on Autonomy and Oversight Model and EHR and Interoperability Depth. Qure AI leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Qure AI and Viz.ai differ most?
The widest separation the AI Health Index records between Qure AI and Viz.ai is on Model and Technology Transparency, where Qure AI grades A and Viz.ai grades B. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Qure AI and Viz.ai grade the same?
The AI Health Index grades Qure AI and Viz.ai the same on several axes, including AI Centrality, Clinical and Operational Evidence and AI Safety and PHI Stewardship. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Qure AI and Viz.ai not disclosed?
At the last review, at least one of Qure AI and Viz.ai published thin or absent detail on Model Supply Chain Disclosure. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
The consequence of a false negative differs sharply between these deployments and buyers should hold that in mind rather than comparing sensitivity figures directly: in a triage and notification deployment the radiologist still reads every study, while in a capacity constrained screening programme the model's output may be the only read a patient receives.
Prevalence compounds this, since identical operating characteristics produce very different positive predictive values in a screening population than in an acute one. Viz.ai publishes no independent security attestation and no business associate terms. Qure publishes complete device dossiers and comparatively little United States commercial assurance material. Neither publishes pricing.